[Featured Stock] Rapid US Expansion with CliaLab Acquisition... LabGenomics 'Strong Performance'

LabGenomics is showing strong performance on the 29th amid securities firms' evaluations that its entry into the U.S. market is accelerating through the acquisition of Eastern QDx and Western IMD CleaLab.

As of 9:45 a.m. on the day, LabGenomics is trading at 3,615 KRW, up 8.07% (270 KRW) from the previous trading day.

On the same day, Daishin Securities analyzed that LabGenomics' LDT strategy will accelerate its penetration into the U.S. diagnostic market.

Founded in 2002, LabGenomics operates NGS-based gene analysis services and manufactures PCR and immunochemical diagnostic kits. It achieved its highest performance during the COVID-19 pandemic through PCR kit testing.

In July 2023, it acquired QDx, and recently added IMD through an additional acquisition, securing a total of four CleaLabs in the U.S.

This content was produced with the assistance of AI translation services.